Three Years of Progress Toward Achieving Hepatitis C Elimination in the Country of Georgia, April 2015–March 2018
| العنوان: | Three Years of Progress Toward Achieving Hepatitis C Elimination in the Country of Georgia, April 2015–March 2018 |
|---|---|
| المؤلفون: | Ekaterine Adamia, Stefan Zeuzem, Francisco Averhoff, Sanjeev Arora, Lia Gvinjilia, Akaki Abutidze, Amiran Gamkrelidze, Nezam H. Afdhal, Muazzam Nasrullah, Beth Skaggs, Karla Thornton, David Metreveli, Nikoloz Chkhartishvili, Maia Butsashvili, Vakhtang Kerashvili, Tengiz Tsertsvadze, Shaun Shadaker, Maia Lagvilava, Lali Sharvadze, Tinatin Kuchuloria, David Sergeenko |
| المصدر: | Clin Infect Dis |
| بيانات النشر: | Oxford University Press (OUP), 2019. |
| سنة النشر: | 2019 |
| مصطلحات موضوعية: | Adult, Microbiology (medical), Ledipasvir, Pediatrics, medicine.medical_specialty, Georgia, Adolescent, Sustained Virologic Response, Sofosbuvir, Hepatitis C virus, Hepacivirus, medicine.disease_cause, Antiviral Agents, Georgia (Republic), 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, medicine, Humans, 030212 general & internal medicine, Articles and Commentaries, Hepatitis, business.industry, Treatment options, Hepatitis C, Hepatitis C, Chronic, medicine.disease, Disease control, Infectious Diseases, chemistry, Virologic response, 030211 gastroenterology & hepatology, business, medicine.drug |
| الوصف: | Background In April 2015, in collaboration with the US Centers for Disease Control and Prevention and Gilead Sciences, the country of Georgia embarked on the world’s first hepatitis C elimination program. We aimed to assess progress toward elimination targets 3 years after the start of the elimination program. Methods We constructed a hepatitis C virus (HCV) care cascade for adults in Georgia, based on the estimated 150 000 persons aged ≥18 years with active HCV infection. All patients who were screened or entered the treatment program during April 2015–March 2018 were included in the analysis. Data on the number of persons screened for HCV were extracted from the national HCV screening database. For the treatment component, we utilized data from the Georgia National HCV treatment program database. Available treatment options included sofosbuvir and ledipasvir/sofosbuvir–based regimens. Results Since April 2015, a cumulative 974 817 adults were screened for HCV antibodies; 86 624 persons tested positive, of whom 61 925 underwent HCV confirmatory testing. Among the estimated 150 000 adults living with chronic hepatitis C in Georgia, 52 856 (35.1%) were diagnosed, 45 334 (30.2%) initiated treatment with direct-acting antivirals, and 29 090 (19.4%) achieved a sustained virologic response (SVR). Overall, 37 256 persons were eligible for SVR assessment; of these, only 29 620 (79.5%) returned for evaluation. The SVR rate was 98.2% (29 090/29 620) in the per-protocol analysis and 78.1% (29 090/37 256) in the intent-to-treat analysis. Conclusions Georgia has made substantial progress in the path toward eliminating hepatitis C. Scaling up of testing and diagnosis, along with effective linkage to treatment services, is needed to achieve the goal of elimination. |
| تدمد: | 1537-6591 1058-4838 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::57bce3b866237363f62293211019e175Test https://doi.org/10.1093/cid/ciz956Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....57bce3b866237363f62293211019e175 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15376591 10584838 |
|---|